Waldenström Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 37-4 - June 30, 2023
- Editors: Jorge J Castillo, Prashant Kapoor, Shayna Sarosiek
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 2 9 8 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 2 9 9 - 0
In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow.
-
Contains 14 practice-oriented topics including clinical implications of genomic profile in Waldenström macroglobulinemia; chemoimmunotherapy regimens in the frontline management of Waldenström macroglobulinemia; management of relapsed or refractory Waldenström macroglobulinemia; evaluation and management of aggressive transformation in Waldenström macroglobulinemia; management of Waldenström macroglobulinemia in limited-resource settings; and more.
-
Provides in-depth clinical reviews of Waldenström macroglobulinemia, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Hematology, oncology
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia
- Key points
- Introduction
- Summary
- Clinics care points
- Disclosures
- Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy
- Key points
- Introduction
- Alkylating agent-based regimens
- Purine-analog based regimens
- Impact of underlying Waldenström macroglobulinemia-related somatic mutations on patient outcomes with chemoimmunotherapy
- Clinics care points
- Conflict of interest
- Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia
- Key points
- Introduction
- Proteasome inhibitors
- New proteasome inhibitors
- Summary
- Clinics care points
- BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia
- Key points
- Introduction
- Current evidence with BTK inhibitors as initial therapy for symptomatic Waldenström macroglobulinemia
- Summary
- Clinics care points
- Disclosure
- Future Directions in the Frontline Management of Waldenström Macroglobulinemia
- Key points
- Asymptomatic patients
- Patients in need of treatment
- Emerging treatments
- The vision of future front-line treatment in Waldenström macroglobulinemia
- Author disclosures
- The Management of Relapsed or Refractory Waldenström’s Macroglobulinemia
- Key points
- Introduction
- Definition relapsed and refractory Waldenström’s macroglobulinemia
- Current treatment options for relapsed/refractory Waldenström’s macroglobulinemia
- Combinations with conventional chemotherapy
- Other emerging treatments
- Which therapy should we choose?
- Clinics care points
- Disclosure
- Funding
- Conflicts of interest
- Novel Agents in Waldenström Macroglobulinemia
- Key points
- Introduction
- Bruton tyrosine kinase inhibitors
- Bruton tyrosine kinase degraders
- Bruton tyrosine kinase inhibitor combinations
- C-X-C chemokine receptor type 4 targeting agents
- Other targeted agents
- Immunotherapies
- Summary
- Clinics care points
- Contributions
- Disclosures
- Investigation and Management of Immunoglobulin M– and Waldenström-Associated Peripheral Neuropathies
- Key points
- Introduction
- Incidence and prevalence
- Prognosis
- Specific immunoglobulin M autoantibody reactivity
- Approach to diagnosis
- Treatment summary
- Summary
- Clinics care points
- Disclosure
- Evaluation and Management of Bing–Neel Syndrome
- Key points
- Introduction
- Epidemiology
- Clinical presentation
- Diagnosis
- Treatment
- Treatment of ocular Bing–Neel syndrome
- Prognosis
- Summary
- Disclosure
- Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia
- Key points
- Introduction and historical perspectives
- Discussion
- Summary
- Clinics care points: recommendations for management of histologic transformation in Waldenström macroglobulinemia
- Authorship
- Management of Waldenström Macroglobulinemia in Limited-Resource Settings
- Key points
- Introduction
- Methods
- Epidemiology of Waldenström macroglobulinemia
- Diagnosis, staging, and risk assessment
- Management
- Final recommendations of the expert panel
- Clinics care points
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 37-4
- Published: June 30, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780443182983
- eBook ISBN: 9780443182990
PK
Prashant Kapoor
Affiliations and expertise
Mayo ClinicSS
Shayna Sarosiek
Affiliations and expertise
Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute